Effect of recombinant adenovirus-mediated endostatin-soluble vascular endothelium growth inhibitor fusion gene on corneal neovascularization

Yong Wang,Lin Liu,Xin Pan
DOI: https://doi.org/10.3321/j.issn:1673-8225.2006.33.037
2006-01-01
Abstract:Aim: To observe the inhibitory and special effects of recombinant adenovirus-mediated endostatin-soluble vascular endothelium growth inhibitor (sVEGI) fusion gene (Ad-hENDO-sVEGI) on proliferation of vascular endothelium cell line. Methods: The experiment was carried out in the laboratory of the Department of Microbiology of the Second Military Medical University of Chinese PLA between June 2002 and June 2003. Recombinant adenovirus-mediated endostatin-soluble vascular endothelium growth inhibitor fusion gene was constructed by routine molecular biology, and identified by enzyme digestion and polymerise chain reaction (PCR). The viral particles were titered by 50% tissue culture infective dose method. Phosphate buffered solution (PBS), Ad-LacZ and Ad-VEGI151 were regarded as control groups with virus titer of MOI=20. When ECV304 and L929 were infected for 4 hours in vitro, the expression of fusion gene mRNA and protein were demonstrated by RT-PCR and Western blot respectively. The bioactivity was determined by Violet crystal assay on day 1, 2, 3, 4, 5 and 7 and represented by absorbance (A) 570/630 nm; the growth curve of ECV304 and L929 was drawn and compared to observe its effects and the specificity. Results: (1) PCR showed that the fusion gene was successfully cloned and tittered 2×108 pfu/mL. (2) Comparison of violet crystal assay results of ECV304 cells in each group: Except the 1st day of infection of the Ad-VEGI151, group (P > 0.05), the A values of ECV304 cells of the Ad-VEGI151, PBS and Ad-LacZ groups were all higher than the Ad-hENDO-sVEGI group (P < 0.01). (3) Comparison of violet crystal assay results of L929 cell of each group: No significant difference was found in the A values of L929 cells among the Ad-hENDO-sVEGI group, PBS group and Ad-LacZ group during group comparison (P > 0.05). Conclusion: The constructed Ad-hENDO-sVEGI can express fuse gene products with bioactivity, and shows a specific synergistic inhibition on proliferation of endothelial cell of vein, which is stronger than that of monogenic products. It can be used in further experiments for treating corneal neovascularization.
What problem does this paper attempt to address?